DavidLWirtaMD
Ophthalmology • Newport Beach, CAOculo-Plastic & Orbital Reconstructive Surgery
Pres./CEO, Eye Research Foundation
Dr. Wirta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
520 Superior Ave
Ste 235
Newport Beach, CA 92663Phone+1 949-650-1863Fax+1 949-650-4359
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical Center/UCLA Stein and Doheny Eye InstitutesResidency, Ophthalmology, 1994 - 1997
Los Angeles County-Harbor-UCLA Medical CenterInternship, Transitional Year, 1993 - 1994
David Geffen School of Medicine at UCLAClass of 1993
Certifications & Licensure
OR State Medical License 1997 - Present
CA State Medical License 1995 - 2026- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:San Diego Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator Start of enrollment: 2016 Jun 01
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease Start of enrollment: 2016 Jun 01
- Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma Start of enrollment: 2018 Mar 23
Publications & Presentations
PubMed
- NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials.William Coleman, Vince Bertucci, Shannon Humphrey, Joely Kaufman-Janette, Terrence Keaney
Aesthetic Surgery Journal. 2024-11-26 - Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution.Jay S Pepose, David Wirta, David Evans, Barbara Withers, Kavon Rahmani
Ophthalmology. 2024-09-16 - Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.David Wirta, William Lipsky, Melissa Toyos, Joseph Martel, John Goosey
BMC Ophthalmology. 2024-07-17
Journal Articles
- Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration with Visual Field in Acquired PtosisCharles B Slonim, Michael S Korenfeld, Robert Smyth-Medina, David L Wirta, JAMA Ophthalmology
Press Mentions
- Understanding Meibomian Gland Dysfunction as a Driver for Dry Eye DiseaseFebruary 14th, 2023
Mallinckrodt : Acthar Gel Phase 4 Keratitis ARVO PosterMay 2nd, 2021- Visus Therapeutics Initiates Phase 2 Clinical Trial of BRIMOCHOL for the Treatment of PresbyopiaMarch 25th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
